Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630663 | 0.92 | CYP3A4 (0.49) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL11013966 | 0.91 | CYP3A4 (0.47) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL9307290 | 0.91 | CYP3A4 (0.47) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL2487834 | 0.91 | CYP3A4 (0.47) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL9306605 | 0.91 | CYP3A4 (0.47) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL12640148 | 0.91 | CA2 (0.50) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL16697003 | 0.89 | CA2 (0.46) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL10623771 | 0.89 | CYP3A4 (0.49) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL11775210 | 0.86 | CYP3A4 (0.44) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL15153778 | 0.84 | CA2 (0.50) | CYP3A4TSHRTDP1ATMCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023114943-A2 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | Acuitas Therapeutics, Inc. (CA) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295075-A1 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | PHOSPHO1, SGMS1, NPC1 | CYP3A4 2030/4885TSHR 2371/4885TDP1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.